| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 40 | 2022 | 849 | 4.200 |
Why?
|
| Graft Rejection | 39 | 2023 | 1065 | 3.540 |
Why?
|
| Liver Transplantation | 25 | 2023 | 1268 | 3.440 |
Why?
|
| Graft Survival | 33 | 2023 | 884 | 2.940 |
Why?
|
| Facial Transplantation | 9 | 2015 | 14 | 2.440 |
Why?
|
| Living Donors | 14 | 2023 | 339 | 2.280 |
Why?
|
| Immunosuppressive Agents | 23 | 2023 | 977 | 2.150 |
Why?
|
| Nephrectomy | 6 | 2018 | 294 | 2.100 |
Why?
|
| Transplantation, Heterologous | 19 | 2022 | 363 | 1.810 |
Why?
|
| Pancreas Transplantation | 6 | 2020 | 103 | 1.350 |
Why?
|
| Vascularized Composite Allotransplantation | 3 | 2019 | 13 | 1.290 |
Why?
|
| Transplantation Chimera | 3 | 2015 | 80 | 1.150 |
Why?
|
| Laparoscopy | 4 | 2018 | 754 | 1.130 |
Why?
|
| Hepatectomy | 3 | 2017 | 166 | 1.130 |
Why?
|
| Chimerism | 2 | 2015 | 37 | 1.070 |
Why?
|
| Transplantation, Homologous | 30 | 2019 | 996 | 1.020 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2017 | 78 | 1.020 |
Why?
|
| Abatacept | 3 | 2019 | 83 | 0.920 |
Why?
|
| Waiting Lists | 4 | 2023 | 175 | 0.910 |
Why?
|
| Swine | 23 | 2022 | 555 | 0.890 |
Why?
|
| Immunoconjugates | 2 | 2014 | 106 | 0.880 |
Why?
|
| Postoperative Complications | 11 | 2020 | 2207 | 0.860 |
Why?
|
| Kidney Failure, Chronic | 7 | 2019 | 509 | 0.830 |
Why?
|
| Bone Marrow | 4 | 2015 | 435 | 0.830 |
Why?
|
| Thrombocytopenia | 4 | 2022 | 183 | 0.820 |
Why?
|
| Alemtuzumab | 3 | 2019 | 83 | 0.800 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 61 | 0.800 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 2022 | 225 | 0.790 |
Why?
|
| Tissue and Organ Procurement | 7 | 2022 | 311 | 0.730 |
Why?
|
| Organ Transplantation | 5 | 2022 | 265 | 0.710 |
Why?
|
| Humans | 93 | 2023 | 86644 | 0.710 |
Why?
|
| Kidney Diseases | 5 | 2023 | 418 | 0.710 |
Why?
|
| Troponin | 1 | 2019 | 24 | 0.710 |
Why?
|
| Male | 58 | 2021 | 40966 | 0.690 |
Why?
|
| Fluid Therapy | 2 | 2018 | 50 | 0.690 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 147 | 0.680 |
Why?
|
| Hepatitis C | 3 | 2021 | 208 | 0.680 |
Why?
|
| Tacrolimus | 7 | 2023 | 373 | 0.680 |
Why?
|
| Heat Stroke | 1 | 2018 | 9 | 0.680 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.670 |
Why?
|
| Face | 5 | 2014 | 114 | 0.660 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 53 | 0.660 |
Why?
|
| Composite Tissue Allografts | 2 | 2015 | 7 | 0.650 |
Why?
|
| Liver | 13 | 2023 | 1230 | 0.640 |
Why?
|
| Terminology as Topic | 1 | 2019 | 217 | 0.630 |
Why?
|
| Retrospective Studies | 23 | 2023 | 8489 | 0.630 |
Why?
|
| Tissue Donors | 7 | 2020 | 463 | 0.620 |
Why?
|
| Isoantibodies | 4 | 2013 | 114 | 0.620 |
Why?
|
| Middle Aged | 34 | 2021 | 25028 | 0.610 |
Why?
|
| Macaca fascicularis | 9 | 2014 | 108 | 0.600 |
Why?
|
| Thymus Gland | 14 | 2005 | 195 | 0.590 |
Why?
|
| Myocardium | 1 | 2019 | 529 | 0.580 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 376 | 0.560 |
Why?
|
| Adult | 32 | 2022 | 25648 | 0.560 |
Why?
|
| Galactosyltransferases | 5 | 2017 | 40 | 0.550 |
Why?
|
| Female | 46 | 2021 | 44533 | 0.550 |
Why?
|
| Hemofiltration | 1 | 2015 | 11 | 0.530 |
Why?
|
| Organ Size | 1 | 2016 | 364 | 0.530 |
Why?
|
| Robotics | 1 | 2018 | 267 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2021 | 567 | 0.510 |
Why?
|
| Intraoperative Care | 1 | 2015 | 82 | 0.510 |
Why?
|
| Papio | 8 | 2015 | 82 | 0.500 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2014 | 6 | 0.490 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 273 | 0.490 |
Why?
|
| Decision Making | 1 | 2019 | 642 | 0.480 |
Why?
|
| Animals | 57 | 2022 | 26582 | 0.470 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 225 | 0.460 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 81 | 0.460 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 26 | 0.450 |
Why?
|
| Laparoscopes | 1 | 2013 | 15 | 0.450 |
Why?
|
| Treatment Outcome | 18 | 2020 | 7993 | 0.450 |
Why?
|
| Animals, Genetically Modified | 9 | 2022 | 181 | 0.440 |
Why?
|
| Biopsy | 9 | 2023 | 1163 | 0.440 |
Why?
|
| Bone Transplantation | 2 | 2011 | 64 | 0.440 |
Why?
|
| HLA Antigens | 3 | 2010 | 232 | 0.430 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.430 |
Why?
|
| Skin Transplantation | 9 | 2009 | 172 | 0.430 |
Why?
|
| Intensive Care Units | 1 | 2015 | 373 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 1373 | 0.400 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 819 | 0.400 |
Why?
|
| Risk Factors | 12 | 2020 | 5417 | 0.400 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 295 | 0.400 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3640 | 0.390 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 295 | 0.380 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 455 | 0.380 |
Why?
|
| Bone Marrow Transplantation | 2 | 2009 | 286 | 0.370 |
Why?
|
| Obesity | 1 | 2016 | 963 | 0.350 |
Why?
|
| Time Factors | 18 | 2021 | 5210 | 0.350 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 107 | 0.350 |
Why?
|
| CD55 Antigens | 5 | 2017 | 20 | 0.350 |
Why?
|
| Sirolimus | 2 | 2009 | 169 | 0.350 |
Why?
|
| Facial Muscles | 1 | 2009 | 23 | 0.340 |
Why?
|
| Aged | 15 | 2021 | 18415 | 0.340 |
Why?
|
| Membrane Cofactor Protein | 4 | 2017 | 10 | 0.340 |
Why?
|
| Prognosis | 6 | 2019 | 3679 | 0.330 |
Why?
|
| Pilot Projects | 3 | 2019 | 839 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 1376 | 0.330 |
Why?
|
| Models, Biological | 1 | 2015 | 1749 | 0.320 |
Why?
|
| Decompression | 1 | 2008 | 3 | 0.320 |
Why?
|
| Autopsy | 3 | 2019 | 116 | 0.320 |
Why?
|
| Boron Neutron Capture Therapy | 3 | 2017 | 11 | 0.320 |
Why?
|
| Gastroparesis | 1 | 2008 | 14 | 0.320 |
Why?
|
| Liver Failure, Acute | 2 | 2018 | 38 | 0.320 |
Why?
|
| Renal Dialysis | 2 | 2010 | 355 | 0.320 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 31 | 0.320 |
Why?
|
| Postoperative Care | 1 | 2008 | 221 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 84 | 0.280 |
Why?
|
| Tissue Scaffolds | 2 | 2017 | 106 | 0.280 |
Why?
|
| Patient Selection | 3 | 2019 | 685 | 0.270 |
Why?
|
| Lung Transplantation | 2 | 2017 | 175 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2020 | 2261 | 0.260 |
Why?
|
| T-Lymphocytes | 6 | 2009 | 1195 | 0.260 |
Why?
|
| Aging | 1 | 2009 | 691 | 0.250 |
Why?
|
| Transplantation Tolerance | 2 | 2003 | 130 | 0.250 |
Why?
|
| Reoperation | 5 | 2020 | 597 | 0.240 |
Why?
|
| Islets of Langerhans | 3 | 2021 | 544 | 0.240 |
Why?
|
| Immune Tolerance | 6 | 2005 | 337 | 0.230 |
Why?
|
| Gene Knockout Techniques | 4 | 2017 | 77 | 0.230 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 763 | 0.230 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 384 | 0.230 |
Why?
|
| Wound Healing | 2 | 2018 | 344 | 0.230 |
Why?
|
| Kava | 1 | 2022 | 3 | 0.220 |
Why?
|
| Histocompatibility Testing | 7 | 2010 | 154 | 0.220 |
Why?
|
| Tongue | 2 | 2013 | 57 | 0.220 |
Why?
|
| Transplant Recipients | 2 | 2021 | 122 | 0.220 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 12 | 0.210 |
Why?
|
| Biomarkers | 3 | 2019 | 1718 | 0.210 |
Why?
|
| Insulin | 4 | 2023 | 1160 | 0.210 |
Why?
|
| Heart Transplantation | 4 | 2017 | 705 | 0.200 |
Why?
|
| Aircraft | 1 | 2021 | 20 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2023 | 125 | 0.200 |
Why?
|
| Head Injuries, Penetrating | 1 | 2022 | 54 | 0.200 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 123 | 0.200 |
Why?
|
| Young Adult | 5 | 2018 | 5976 | 0.200 |
Why?
|
| Models, Animal | 3 | 2013 | 263 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2023 | 300 | 0.190 |
Why?
|
| Survival Rate | 3 | 2019 | 1863 | 0.190 |
Why?
|
| Heterografts | 2 | 2017 | 98 | 0.190 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 86 | 0.190 |
Why?
|
| Complement C4b | 2 | 2010 | 35 | 0.190 |
Why?
|
| Maryland | 3 | 2015 | 35 | 0.190 |
Why?
|
| Renin | 1 | 2020 | 79 | 0.190 |
Why?
|
| Angiotensin II | 1 | 2020 | 94 | 0.190 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 53 | 0.180 |
Why?
|
| Glioma | 4 | 2017 | 285 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 126 | 0.180 |
Why?
|
| Length of Stay | 3 | 2016 | 702 | 0.180 |
Why?
|
| Drainage | 1 | 2020 | 157 | 0.180 |
Why?
|
| Aneurysm, Infected | 1 | 2019 | 12 | 0.180 |
Why?
|
| Aftercare | 1 | 2020 | 85 | 0.180 |
Why?
|
| Donor Selection | 2 | 2017 | 67 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2020 | 102 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 133 | 0.170 |
Why?
|
| Patient Compliance | 1 | 2020 | 227 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 2019 | 54 | 0.170 |
Why?
|
| Hepatic Artery | 1 | 2019 | 83 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 143 | 0.170 |
Why?
|
| Transplantation Immunology | 7 | 2005 | 84 | 0.170 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 35 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 160 | 0.160 |
Why?
|
| Extracorporeal Circulation | 2 | 2017 | 26 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2010 | 460 | 0.160 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2009 | 74 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2020 | 238 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1673 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2019 | 129 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2232 | 0.160 |
Why?
|
| Sorption Detoxification | 1 | 2017 | 2 | 0.160 |
Why?
|
| Fatal Outcome | 2 | 2017 | 293 | 0.160 |
Why?
|
| Liver, Artificial | 1 | 2017 | 7 | 0.160 |
Why?
|
| Motivation | 1 | 2020 | 287 | 0.160 |
Why?
|
| Neuraminic Acids | 1 | 2017 | 10 | 0.160 |
Why?
|
| Consensus | 1 | 2019 | 335 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2018 | 248 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 3 | 2010 | 144 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 150 | 0.150 |
Why?
|
| Hernia, Umbilical | 1 | 2017 | 17 | 0.150 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2017 | 10 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 52 | 0.150 |
Why?
|
| Mycophenolic Acid | 2 | 2022 | 87 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 139 | 0.150 |
Why?
|
| Equipment Design | 2 | 2021 | 406 | 0.150 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2016 | 3 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2019 | 349 | 0.150 |
Why?
|
| Antilymphocyte Serum | 9 | 2009 | 71 | 0.150 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2019 | 208 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 51 | 0.150 |
Why?
|
| Bile Ducts | 1 | 2016 | 59 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 185 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 1204 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 174 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 237 | 0.140 |
Why?
|
| Kidney | 8 | 2022 | 1241 | 0.140 |
Why?
|
| Thymidine | 4 | 2013 | 59 | 0.140 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 218 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 240 | 0.140 |
Why?
|
| Patient Safety | 1 | 2018 | 212 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2019 | 265 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2017 | 181 | 0.140 |
Why?
|
| Brain Death | 2 | 2013 | 69 | 0.130 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 22 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 9 | 0.130 |
Why?
|
| Violence | 1 | 2017 | 143 | 0.130 |
Why?
|
| Thymidine Kinase | 2 | 2013 | 30 | 0.130 |
Why?
|
| Swine, Miniature | 10 | 2004 | 51 | 0.130 |
Why?
|
| Histocompatibility | 5 | 2017 | 71 | 0.130 |
Why?
|
| Eukaryotic Initiation Factor-4A | 1 | 2014 | 2 | 0.130 |
Why?
|
| Guanylate Cyclase | 1 | 2014 | 18 | 0.130 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 15 | 0.130 |
Why?
|
| Anastomosis, Surgical | 2 | 2022 | 267 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2023 | 2767 | 0.130 |
Why?
|
| Preimplantation Diagnosis | 1 | 2014 | 5 | 0.130 |
Why?
|
| Hand Transplantation | 1 | 2014 | 1 | 0.130 |
Why?
|
| Forearm | 1 | 2014 | 32 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 136 | 0.120 |
Why?
|
| United States | 6 | 2023 | 6672 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2014 | 57 | 0.120 |
Why?
|
| Stents | 2 | 2019 | 377 | 0.120 |
Why?
|
| Lymphangiogenesis | 1 | 2014 | 38 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2015 | 476 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 394 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 62 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2014 | 37 | 0.120 |
Why?
|
| Skin | 4 | 2014 | 554 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2021 | 510 | 0.120 |
Why?
|
| Endoscopy | 1 | 2017 | 332 | 0.120 |
Why?
|
| Nucleoside Transport Proteins | 1 | 2013 | 2 | 0.120 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 113 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 212 | 0.120 |
Why?
|
| Boron Compounds | 1 | 2013 | 20 | 0.120 |
Why?
|
| Primates | 1 | 2015 | 151 | 0.120 |
Why?
|
| Ligation | 1 | 2013 | 51 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 999 | 0.110 |
Why?
|
| B7-2 Antigen | 1 | 2013 | 40 | 0.110 |
Why?
|
| Cytomegalovirus | 2 | 2004 | 76 | 0.110 |
Why?
|
| Virus Activation | 2 | 2004 | 41 | 0.110 |
Why?
|
| Facial Injuries | 1 | 2013 | 19 | 0.110 |
Why?
|
| B7-1 Antigen | 1 | 2013 | 75 | 0.110 |
Why?
|
| Multiple Trauma | 1 | 2013 | 34 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 297 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2017 | 1538 | 0.110 |
Why?
|
| CD28 Antigens | 1 | 2013 | 88 | 0.110 |
Why?
|
| Ganciclovir | 2 | 2010 | 49 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2016 | 770 | 0.110 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2012 | 18 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 120 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2013 | 971 | 0.110 |
Why?
|
| Jaw | 1 | 2013 | 61 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 4214 | 0.110 |
Why?
|
| Spouses | 1 | 2012 | 33 | 0.110 |
Why?
|
| Ureteral Diseases | 1 | 2012 | 14 | 0.110 |
Why?
|
| Photography | 1 | 2012 | 37 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1169 | 0.100 |
Why?
|
| Fibula | 1 | 2011 | 32 | 0.100 |
Why?
|
| Bone Regeneration | 1 | 2011 | 52 | 0.100 |
Why?
|
| Wounds, Gunshot | 1 | 2013 | 71 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 76 | 0.100 |
Why?
|
| Perfusion | 2 | 2022 | 203 | 0.100 |
Why?
|
| Microsurgery | 1 | 2011 | 84 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 68 | 0.100 |
Why?
|
| Abdominal Wall | 1 | 2011 | 30 | 0.100 |
Why?
|
| Regeneration | 1 | 2012 | 143 | 0.100 |
Why?
|
| Technetium | 3 | 1974 | 29 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 62 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1801 | 0.090 |
Why?
|
| Creatinine | 2 | 2009 | 338 | 0.090 |
Why?
|
| Antibodies, Heterophile | 3 | 2001 | 20 | 0.090 |
Why?
|
| Parents | 1 | 2012 | 272 | 0.090 |
Why?
|
| B-Lymphocytes | 4 | 2014 | 724 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2011 | 241 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 263 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 29 | 0.090 |
Why?
|
| Transplantation, Heterotopic | 3 | 2003 | 45 | 0.080 |
Why?
|
| Femoral Vein | 1 | 2009 | 35 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 429 | 0.080 |
Why?
|
| Cadaver | 1 | 2009 | 185 | 0.080 |
Why?
|
| Jugular Veins | 1 | 2009 | 69 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 55 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 92 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 114 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2021 | 873 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 930 | 0.080 |
Why?
|
| Disulfiram | 1 | 1987 | 8 | 0.080 |
Why?
|
| Lymphocytes | 7 | 2000 | 464 | 0.080 |
Why?
|
| Survivors | 1 | 2009 | 226 | 0.080 |
Why?
|
| Rats | 7 | 2017 | 3990 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1987 | 69 | 0.070 |
Why?
|
| Antibody Formation | 6 | 1999 | 171 | 0.070 |
Why?
|
| Baltimore | 2 | 2020 | 36 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 859 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.070 |
Why?
|
| Child | 4 | 2023 | 6927 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2017 | 297 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 1 | 2006 | 54 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 262 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2001 | 425 | 0.070 |
Why?
|
| Organ Preservation | 2 | 2022 | 83 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2009 | 409 | 0.070 |
Why?
|
| Algorithms | 1 | 2013 | 1830 | 0.060 |
Why?
|
| Pancreatectomy | 2 | 2002 | 148 | 0.060 |
Why?
|
| Gammaherpesvirinae | 1 | 2004 | 1 | 0.060 |
Why?
|
| Adolescent | 4 | 2017 | 8981 | 0.060 |
Why?
|
| Animals, Newborn | 4 | 2016 | 510 | 0.060 |
Why?
|
| Antibodies | 3 | 2003 | 350 | 0.060 |
Why?
|
| Bilirubin | 2 | 2023 | 125 | 0.060 |
Why?
|
| Renal Replacement Therapy | 1 | 2023 | 30 | 0.060 |
Why?
|
| Acute Disease | 4 | 2010 | 826 | 0.060 |
Why?
|
| Anatomic Landmarks | 2 | 2013 | 31 | 0.060 |
Why?
|
| Omentum | 1 | 2003 | 71 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2023 | 73 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2023 | 73 | 0.060 |
Why?
|
| Immunity, Cellular | 6 | 1992 | 177 | 0.060 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2022 | 9 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 50 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 114 | 0.050 |
Why?
|
| Glioblastoma | 2 | 2005 | 255 | 0.050 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
| Heme Oxygenase-1 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Mice | 17 | 2013 | 11352 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 103 | 0.050 |
Why?
|
| Tissue Transplantation | 1 | 2001 | 12 | 0.050 |
Why?
|
| Haplotypes | 2 | 2001 | 642 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 2 | 2000 | 60 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1753 | 0.050 |
Why?
|
| Resuscitation | 1 | 2022 | 100 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2005 | 485 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 920 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 177 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 127 | 0.050 |
Why?
|
| Transplantation, Autologous | 2 | 1999 | 331 | 0.050 |
Why?
|
| Lymphocyte Depletion | 3 | 1998 | 97 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2002 | 163 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2022 | 143 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 69 | 0.050 |
Why?
|
| Borohydrides | 1 | 2000 | 7 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2818 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 860 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 153 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 159 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 98 | 0.050 |
Why?
|
| Astrocytoma | 1 | 2000 | 82 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2021 | 159 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 213 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 2000 | 69 | 0.050 |
Why?
|
| Standard of Care | 1 | 2020 | 79 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 3362 | 0.050 |
Why?
|
| Registries | 1 | 2023 | 702 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 1979 | 44 | 0.040 |
Why?
|
| Killer Cells, Natural | 3 | 2001 | 267 | 0.040 |
Why?
|
| Lymphocyte Subsets | 3 | 2014 | 64 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2000 | 170 | 0.040 |
Why?
|
| Immunoglobulin M | 3 | 2001 | 154 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 239 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2014 | 782 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 6 | 1998 | 1047 | 0.040 |
Why?
|
| Antigens, Heterophile | 1 | 1998 | 6 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 736 | 0.040 |
Why?
|
| Software | 1 | 2023 | 654 | 0.040 |
Why?
|
| Cytokines | 1 | 2022 | 776 | 0.040 |
Why?
|
| Kupffer Cells | 1 | 2017 | 13 | 0.040 |
Why?
|
| Transfection | 2 | 2013 | 896 | 0.040 |
Why?
|
| Spleen | 5 | 2001 | 430 | 0.040 |
Why?
|
| Mice, SCID | 1 | 1998 | 252 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 365 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 1999 | 559 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 912 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 879 | 0.040 |
Why?
|
| Neutrophils | 1 | 1979 | 307 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6509 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2019 | 228 | 0.040 |
Why?
|
| Isotope Labeling | 2 | 1974 | 51 | 0.040 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2013 | 1106 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 3 | 2003 | 81 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 48 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2017 | 127 | 0.040 |
Why?
|
| Antibody-Producing Cells | 4 | 1972 | 16 | 0.040 |
Why?
|
| Thymectomy | 3 | 2002 | 31 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 69 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.040 |
Why?
|
| Social Support | 1 | 2018 | 193 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 384 | 0.040 |
Why?
|
| Spinal Cord | 2 | 2017 | 249 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 865 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 814 | 0.040 |
Why?
|
| Albumins | 1 | 2016 | 133 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 468 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1979 | 728 | 0.030 |
Why?
|
| Immune Sera | 3 | 1971 | 52 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2015 | 244 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
| Disaccharides | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 273 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 127 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 112 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 849 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2014 | 458 | 0.030 |
Why?
|
| Complement Activation | 1 | 2015 | 81 | 0.030 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2014 | 6 | 0.030 |
Why?
|
| Homozygote | 2 | 2009 | 200 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 157 | 0.030 |
Why?
|
| Triterpenes | 1 | 2014 | 7 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 916 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 6 | 2000 | 3092 | 0.030 |
Why?
|
| Brain | 3 | 2017 | 2216 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 49 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 428 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 44 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2426 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 118 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 943 | 0.030 |
Why?
|
| Caspases | 1 | 2014 | 155 | 0.030 |
Why?
|
| Rats, Inbred Strains | 1 | 2014 | 312 | 0.030 |
Why?
|
| Interferons | 2 | 1977 | 133 | 0.030 |
Why?
|
| Complement Inactivator Proteins | 1 | 1974 | 27 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 746 | 0.030 |
Why?
|
| Hindlimb | 1 | 2014 | 89 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 27 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 199 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 163 | 0.030 |
Why?
|
| DNA | 2 | 2016 | 1294 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 1992 | 123 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1014 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 151 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2013 | 287 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 302 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1972 | 37 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2013 | 347 | 0.030 |
Why?
|
| Biological Transport | 1 | 2013 | 396 | 0.030 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1972 | 47 | 0.030 |
Why?
|
| Models, Educational | 1 | 2012 | 50 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 378 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 246 | 0.030 |
Why?
|
| Facial Expression | 1 | 2012 | 51 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2004 | 265 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 329 | 0.030 |
Why?
|
| Rabbits | 5 | 1993 | 636 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2012 | 96 | 0.030 |
Why?
|
| Eosinophilia | 1 | 1972 | 84 | 0.030 |
Why?
|
| Radius | 1 | 2011 | 29 | 0.030 |
Why?
|
| Fluorescence | 1 | 2012 | 102 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 67 | 0.020 |
Why?
|
| Hyperbilirubinemia, Hereditary | 1 | 1971 | 3 | 0.020 |
Why?
|
| Pigments, Biological | 1 | 1971 | 14 | 0.020 |
Why?
|
| Angiography | 1 | 2011 | 208 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1971 | 31 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 532 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 969 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 1971 | 48 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Cell Movement | 1 | 1974 | 758 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1992 | 315 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2010 | 64 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 674 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2013 | 434 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2001 | 11 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 397 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 2005 | 156 | 0.020 |
Why?
|
| Cell Separation | 2 | 2005 | 196 | 0.020 |
Why?
|
| Sheep | 4 | 1974 | 239 | 0.020 |
Why?
|
| Diuresis | 1 | 2009 | 29 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 2009 | 26 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2001 | 203 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 76 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2468 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 2271 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 213 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2003 | 1686 | 0.020 |
Why?
|
| Cell Division | 2 | 1999 | 696 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 469 | 0.020 |
Why?
|
| Kinetics | 2 | 2005 | 1513 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 2 | 1998 | 41 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2010 | 319 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 1577 | 0.020 |
Why?
|
| Alcoholism | 1 | 1987 | 172 | 0.020 |
Why?
|
| Macrophages | 1 | 1969 | 554 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2005 | 45 | 0.020 |
Why?
|
| Autoradiography | 2 | 1979 | 69 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 123 | 0.020 |
Why?
|
| Mice, Inbred A | 2 | 1974 | 23 | 0.020 |
Why?
|
| Sarcoma, Experimental | 2 | 1974 | 53 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2005 | 121 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 46 | 0.020 |
Why?
|
| Lymph Nodes | 3 | 1974 | 533 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3241 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 646 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 16 | 0.010 |
Why?
|
| Hemolytic Plaque Technique | 3 | 1972 | 12 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 439 | 0.010 |
Why?
|
| Mice, Inbred Strains | 2 | 2001 | 307 | 0.010 |
Why?
|
| Surgically-Created Structures | 1 | 2002 | 5 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 679 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 234 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 1 | 2002 | 9 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 2002 | 17 | 0.010 |
Why?
|
| Thrombosis | 1 | 2005 | 296 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2002 | 116 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2001 | 19 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1974 | 503 | 0.010 |
Why?
|
| Mesentery | 1 | 2001 | 45 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2002 | 303 | 0.010 |
Why?
|
| Mediastinum | 1 | 2001 | 46 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3612 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 458 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2002 | 176 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2001 | 27 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2001 | 63 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 2 | 1974 | 250 | 0.010 |
Why?
|
| Lung | 2 | 2002 | 1170 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 560 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1961 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2001 | 158 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 2000 | 16 | 0.010 |
Why?
|
| Biological Availability | 1 | 2000 | 92 | 0.010 |
Why?
|
| Pneumonia | 1 | 2002 | 179 | 0.010 |
Why?
|
| Radiometry | 1 | 2000 | 53 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 678 | 0.010 |
Why?
|
| Blood Cells | 1 | 2000 | 33 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2000 | 23 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2000 | 66 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 712 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 290 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 299 | 0.010 |
Why?
|
| Erythrocytes | 2 | 1972 | 255 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2000 | 292 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1999 | 39 | 0.010 |
Why?
|
| Phenotype | 2 | 1998 | 2378 | 0.010 |
Why?
|
| Peritoneum | 1 | 1998 | 57 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2000 | 429 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 927 | 0.010 |
Why?
|
| Rabies | 1 | 1977 | 7 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1981 | 0.010 |
Why?
|
| Genetics | 1 | 1956 | 24 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1998 | 790 | 0.010 |
Why?
|
| Leukocytes | 1 | 1977 | 202 | 0.010 |
Why?
|
| Allografts | 1 | 1956 | 172 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1992 | 989 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1956 | 269 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1974 | 28 | 0.010 |
Why?
|
| Venoms | 1 | 1974 | 12 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1974 | 84 | 0.010 |
Why?
|
| Tritium | 1 | 1974 | 133 | 0.010 |
Why?
|
| Methods | 1 | 1974 | 152 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1974 | 70 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1993 | 171 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1993 | 71 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1993 | 186 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1974 | 391 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1993 | 81 | 0.010 |
Why?
|
| Perissodactyla | 1 | 1972 | 1 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1972 | 4 | 0.010 |
Why?
|
| Absorption | 1 | 1972 | 25 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1972 | 27 | 0.010 |
Why?
|
| Hepatomegaly | 1 | 1972 | 15 | 0.010 |
Why?
|
| Agammaglobulinemia | 1 | 1972 | 20 | 0.010 |
Why?
|
| Fibroblasts | 2 | 1979 | 729 | 0.010 |
Why?
|
| Immunity | 1 | 1972 | 136 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1998 | 1458 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1991 | 106 | 0.010 |
Why?
|
| Liver Glycogen | 1 | 1971 | 5 | 0.010 |
Why?
|
| Hexosamines | 1 | 1971 | 5 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1971 | 27 | 0.010 |
Why?
|
| Glycoside Hydrolases | 1 | 1971 | 17 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1971 | 130 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1972 | 232 | 0.010 |
Why?
|
| Lysosomes | 1 | 1971 | 104 | 0.010 |
Why?
|
| Mitochondria | 1 | 1974 | 535 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 1041 | 0.010 |
Why?
|
| Newcastle disease virus | 1 | 1969 | 2 | 0.010 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1969 | 16 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 1 | 1969 | 2 | 0.010 |
Why?
|
| Iodine Isotopes | 1 | 1969 | 18 | 0.010 |
Why?
|
| Salmonella typhi | 1 | 1969 | 7 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 1969 | 30 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1969 | 97 | 0.010 |
Why?
|
| Flagella | 1 | 1969 | 25 | 0.010 |
Why?
|
| Antigens | 1 | 1969 | 228 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1972 | 2380 | 0.000 |
Why?
|
| Pregnancy | 1 | 1993 | 2894 | 0.000 |
Why?
|
| Neoplasms | 1 | 1956 | 2898 | 0.000 |
Why?
|
| Rabies virus | 1 | 1977 | 5 | 0.000 |
Why?
|
| Injections, Spinal | 1 | 1977 | 44 | 0.000 |
Why?
|
| Haplorhini | 1 | 1977 | 81 | 0.000 |
Why?
|
| Time | 1 | 1977 | 77 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1977 | 293 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1972 | 11 | 0.000 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1969 | 6 | 0.000 |
Why?
|
| Colloids | 1 | 1969 | 25 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1969 | 102 | 0.000 |
Why?
|
| Phagocytosis | 1 | 1969 | 85 | 0.000 |
Why?
|
| Carbon | 1 | 1969 | 80 | 0.000 |
Why?
|